Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

BeiGene’s Tevimbra approved by FDA for first-line oesophageal cancer use

Oesophageal squamous cell carcinoma accounts for nearly 90% of all oesophageal cancers

- PMLiVE

Luto expands to Switzerland with new office

The Basel office places the company at the heart of Europe’s life sciences sector

- PMLiVE

Setting your sights – the marketing objectives that guide everything that follows

Strong brands need clear objectives – the four steps to avoiding wombat marketing

- PMLiVE

J&J receives three CHMP recommendations for immunology and oncology indications

Tremfya, Stelara and Darzalex have been recommended for ulcerative colitis, Crohn’s disease and multiple myeloma, respectively

- PMLiVE

Sobi receives NICE recommendation for Altuvoct in severe haemophilia A

Approximately 7,700 people in England are living with the genetic bleeding disorder

- PMLiVE

MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

The drug has been authorised to treat patients with moderate-to-severe cases of the skin diseases

- PMLiVE

The full potential of patient journeys in pharma

Unlocking three actions to take now

- PMLiVE

Navigating market access: Launch strategies and health economic modelling for medical devices – a live panel discussion

Discover how health economics can support successful Medical Device launch, proposition development, and market access. Join us live at 1:30pm (GMT) on Wednesday 19th March for an insightful journey into...

Petauri Evidence

- PMLiVE

Rare diseases: Novartis’ Fabhalta recommended by CHMP for C3 glomerulopathy

Approximately one to two people per million worldwide are diagnosed with the ultra-rare kidney disease every year

EU flag

Rare diseases: CHMP recommends Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

There is currently only one treatment authorised for the ultra-rare genetic blistering disease

- PMLiVE

Key clinical trial trends – EU vs US perspectives

Highlighting the distinct priorities and hurdles faced by sponsors, CROs and sites around the world

- PMLiVE

Rare Disease Day 2025 – highlighting recent approvals in the rare disease space

There are more than 7,000 known rare diseases that impact 300 million people globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links